求助书籍

wenwen629

Dübel, Stefan (ed.)
: q  J$ P2 x: i. rHandbook of Therapeutic Antibodies
- Y  A8 W/ e7 w% @Technologies, Emerging Developments and Approved Therapeutics
0 W5 m+ h9 N! h
* ^9 W/ V" ^* D3 m1 R1. Edition - July 2010* Q3 {$ q/ Q2 D. {. F; h4 G- A
199.- Euro/ l) x7 ^: ~$ Y3 a$ u( A
2010. XLVI, 1204 Pages, Softcover
% p8 c3 D" b4 u4 }2 I! A200 Fig. (100 Colored Fig.)3 c4 G9 K4 t  S+ s) [: R. I) l: [, w
- Handbook/Reference Book -
% N% z% ?" R  Y7 ?* f3 sISBN-10: 3-527-32902-1- z+ c. d+ n+ f, Y4 X! n; {
有目录也可，求书！

hdc2001

我也想要。

hdc2001

Section I: Technologies
  ^) t1 O& d  W- ^. D( {  W9 pForeword
2 B$ T+ ~/ T4 C6 E% SA Greeting from the Editor
, R$ n. `1 m, u' `( n5 l, j, y  DPART 0: INTRODUCTION9 l2 v5 k8 `. z8 j5 q! a8 {, F  ^
Therapeutic Antibodies - From Past to Future
9 X# C; ^. A( ]- g8 t- LPART I: SELECTING AND SHAPING THE ANTIBODY MOLECULE
4 ]8 S! u1 k7 A, tSelection strategies I: Monoclonal Antibodies
' U  U- M2 [2 ]3 x" n, p4 }" W- `Selection strategies II: Antibody Phage Display/ `/ g" N4 m9 d; b2 _1 t
Selection strategies III: Transgenic Mice7 s3 [. Q; J, h% D- [5 |) O
Bioinformatic Tools for Antibody Engineering
1 Z, G. O: ]# k0 JMolecular Engineering I: Humanization
) x+ w! t  h& V- uMolecular Engineering II: Affinity Maturation 4 m# O+ X& Y+ [- B* W/ U& V
Molecular Engineering III: Fc Engineering2 \# i. }: A2 w2 ]- g. N  t
PART II: THE WAY INTO THE CLINIC- {  O$ M3 ^* U1 A( H- A& b
Production and Downstream Processing
+ N0 \7 b* c7 d# y9 u7 C0 FPharmaceutical Formulation and Clinical Application. J- m+ \# H$ D& v7 x1 |' W
Immunogenicity of Antibody Therapeutics
; O0 @/ z; |7 h. k: l: N' a4 QRegulatory Considerations* G! X. i$ b% K0 U7 x' a8 b! P
Intellectual Property Issues
* E5 ?; m7 [3 S  Q+ m! l  I3 |$ [) V; q1 u( B8 h& b) a# }
Section II: Emerging Developments7 O/ w8 S) r+ D7 |
PART III: BEYOND IGG: MODIFIED ANTIBODIES
- X+ y0 I( ?3 ~, [# pImmunoscintigraphy and Radioimmunotherapy : Q5 ^8 r* G0 d9 @0 [0 M9 C) `
Bispecific Antibodies ' L( @% A4 P7 }; P4 \$ m
Immunotoxins /6 \' M- }0 x. t0 B7 Y% S
Targeted RNases
( s% [5 J5 G1 j$ @8 ~PART IV: EMERGING CONCEPTS
$ p3 [) l/ ~3 |) ~Automation of Selection and Engineering
, m3 }! {# i: t  s! [, l, `; gEmerging Technologies for Antibody Selection
& ?3 h0 b$ b$ v6 WEmerging Alternative Production Systems 2 S& _  O) V  k; P# P
Non-Antibody Scaffolds ' ^6 Q2 k# }8 B  y& K9 J
Emerging Therapeutic Concepts I: ADEPT/ ?6 U: j1 m8 x& l- ]
Emerging Therapeutic Concepts II: Nanotechnology & v. W0 [- F# J; ?1 V: T  ?3 j
Emerging Therapeutic Concepts III:Cell-bound antibodies. R( Y+ N; S$ s8 W3 n% q7 K
Emerging Therapeutic Concepts IV:Anti-idiotypic Antibodies# X1 X+ W) R" P! ^% ]- s+ e/ r
PART V: ONGOING CLINICAL STUDIES:9 l: L7 G! q1 C- M* S
Antibodies in Phase I/II/III: Cancer Therapy
1 E" c3 S! O7 k; ]+ wAntibodies in Phase I/II/III: Targeting TNF. m6 F7 j3 x; T8 q4 u- R
, }6 I! g6 H) t; e  [
Section III: APPROVED THERAPEUTICS( t+ I' L! j4 y! A; R: R7 R% C
Adalimumab (Humira)
& ~6 W# D( D5 w- e9 b0 n( aAlemtuzumab (Mabcampath)
8 Q! o  Y7 D1 q3 E) F4 d& t2 t5 N1 ~Bevacizumab (Avastin)
7 a& c& F% D  i: }Cetuximab (Erbitux)
% H$ Z: c! \; p4 g, @  iEfalizumab (Raptiva)
9 a+ ~, q( C5 v$ W; N. V. gFanolesomab/Technetium99m (Neutrospec)
. w' |' |- Z- n4 z9 I6 v3 PGemtuzumab Ozogamicin (Mylotarg)2 d4 S  z7 B. j. ]
Infliximab (Remicade)
! e# i, _0 j/ qMuromonab (Orthoclone)
- j0 F! Y$ `' \% \. O' f3 U  kNatalizumab (Tysabri)9 b6 X" t( I" F1 J
Omalizumab (Xolair)1 Z' ^+ C) N! t& V- X! H
Palivizumab (Synagis): \' E8 |. o2 s' b
Rituximab (Rituxan)( A1 U( `& x7 N+ m3 [5 e
Trastuzumab (Herceptin)9 G# F/ c' i9 ?# L- j
Overview: Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab and Votumumab% Y" \" s9 m) ?/ i. p- M  z
Yttrium-90 Ibritumomab Tiuxetan (Zevalin)
! Y+ B0 m2 ~, z  g* h

wenwen629

回复 hdc2001 的帖子
" W2 i  x9 j) I  l4 Q/ S6 A! \4 y- t1 D6 B) H; N, Q! J  F+ a
谢谢。